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It is therefore of great importance that researchers clearly communicate which assumptions they have had to make, and which inherent limitations apply to the interpretation of their results. This review discusses considerations of, and the underlying assumptions for, utilizing different response phenotypes and study designs popular in pharmacogenetic research to infer gene-treatment interaction effects, with a special focus on those dealing with of clinical effects of drug treatment.
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| INTRODUCTION
Pharmacogenetics can be thought of as a classic example of geneenvironment interaction. Namely, in the search for genetic variation which can explain inter-individual drug response variability, researchers typically aim to answer the question whether a treatment effect differs between subjects with different genotypes. In other words, whether an inherited genetic variant acts as an effect measure modifier for a certain (drug) treatment.
Although the term pharmacogenetics was coined halfway through the 20th century by Vogel, 1 widespread interest into the field truly emerged with the completion of the Human Genome Project 2 ( Figure 1 ). There now exist large publically available web resources and pharmacogenetic databases, made possible by methodological advances in sequencing technology and the emergence of genome-wide testing strategies. 3, 4 Regrettably, contemporary pharmacogenetic research often depends on the type of study data readily available, as most epidemiological studies are not developed with pre-specified pharmacogenetic research questions in mind.
Therefore, a heterogeneous body of literature exists. Collective interpretation can be difficult, as limitations and assumptions inherent to different epidemiological study designs must be recognised.
Unfortunately, there also exist notable examples in the literature where authors overextend the scope and significance of their findings.
Here, we discuss considerations relating to different response phenotypes and study designs typically found throughout the pharmacogenetic literature. Although many of the considerations and pitfalls described in this study will also apply to other types of pharmacogenetic investigations (eg, those focussing on absorption, distribution, metabolism and excretion [ADME] properties), we will especially focus on studies dealing with clinical effects of drug treatment, an area where we feel invalid inference is more prevalent or at least more visible. We will clarify which conclusions may be drawn and which limitations naturally follow from which methodological approach. Where applicable we provide illustrative examples from the field of statin pharmacogenetics, in which a diverse range of phenotypes and study designs have been combined and investigated. 5 Here, we will focus specifically on investigations into the intended effects of cholesterol reduction, on the prevention of vascular events, or on the unintended occurrence of myopathyrelated complaints after starting statin therapy.
| RESPONSE PHENOTYPES
Except for sharply defined clinical outcomes such as mortality, effects of treatment can often be visualised as lying on a possible spectrum of outcomes. For example, the clinical spectrum of statin-induced myopathy ranges from commonly occurring myalgia to very rare incidents of life threatening rhabdomyolysis. 6 The narrow approach of dichotomization will thus lead to a loss of information and possibly reduced statistical power. 7 This may particularly be the case for drug efficacy or toxicity phenotypes related to drug dosage. Furthermore, dichotomizing outcomes may induce unnecessary phenotypic heterogeneity between studies (complicating systemic reviews and metaanalyses), and might conceal possible non-linearity in the associations under investigation. Therefore, continuously distributed outcometraits are often preferable when available. However, these outcomes come with their own challenges (eg, non-normal distributions), and may hinder translating the results to clinically meaningful findings.
For example, prior knowledge of clear clinical bimodality (eg, disease remission) may guide researchers in choosing a response phenotype which most closely aligns with the biology of interest. In addition, dichotomous outcomes more often allow for simple visual presentation of results and categorization may mitigate the effects of including significant outliers in your analysis.
Most pharmacogenetic investigations of interest are inherently longitudinal in nature, as one wishes to measure a phenotype just before and then after a drug treatment has started. This goal corresponds to a criterion essential to causal inference, namely temporality: that exposure preceded the outcome (ie, onset of disease or change over time in a trait). 8 Even for binary outcomes (eg, clinical or adverse events) it will be essential to compare incidence between drug exposure categories, including the absence of drug exposure.
Whenever possible, incorporating both on-and off-treatment observations into the data analysis is therefore considered superior to solely basing conclusions on data from one or more observations made on-treatment. There exist additional reasons why utilizing repeated measurements is often preferable for quantitative traits.
Firstly, a single measurement is merely a snapshot of the underlying response-curve, not representative of the true response characteristics over the whole treatment phase, which is likely to differ per individual. 9 Secondly, methods that do involve baseline values can eliminate much of the between-subject variability from the treatment comparison, and are therefore typically more powerful. Thirdly, limiting the analysis to a single on-treatment value ignores possible baseline imbalances between the groups, which are likely to occur in nonrandomised studies. Taking these into account may help to control for confounding by (contra)indication and in distinguishing genetic effects on the response phenotype from those on off-treatment levels. Finally, having both on-and off-treatment measurements allows for the calculation of change over time, which is easy to communicate to a broad non-statistical audience.
A further consideration is the selection of a valid time interval to assess treatment response, which should be based on clinical experience. For example, a steady-state in low-density lipoprotein cholesterol (LDL-C) may be expected 4 to 6 weeks after start of statin treatment. 10 However, when one is interested in onset of myopathy symptoms a longer period should be considered, for example, the mean duration of statin therapy before onset of symptoms was 6.3 months (range 0.25-48.0) in a retrospective study of 45 patients.
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For adverse drug reactions, response phenotypes suitable for pharmacogenetic research will generally be those which appear to be strongly tied to the drug exposure. This will often depend on baseline disease incidence, whether relative effect sizes observed in largescale studies are of apparent clinical importance, but also whether sufficient evidence supports a causal link between the drug exposure and the adverse event. Additional practical considerations such as data availability may guide or limit researchers in their investigations.
For example, while it has been reliably shown that new-onset diabetes mellitus may be caused by statin therapy, 12 repeated glucose measurements have historically not been assessed within statin trials.
This likely explains why statin-induced glucose changes have not been examined in the pharmacogenetic setting to date.
| DEFINING TREATMENT EFFECT
The observed average treatment response in a study does not always reflect the benefit of the treatment per se, as the context wherein this observation is made is of great importance ( Figure 2 ). This is because an individuals' treatment response, defined here as the clinical outcome after starting the treatment, is not just a combination of the drug effect (ie, the underlying (un)measured physiochemical response) and the natural course of the disease, but may also reflect secondary effects of initiating drug treatment. 13, 14 Examples include placebo effects, the possibility that the individual may have been motivated to concurrently alter lifestyle habits of prognostic significance to the outcome of interest, or that the researcher or study participant may (un)knowingly influence the measurement of the endpoint if he/she is aware of the purpose of the study (ie, observer bias). 14 The latter issue is more likely to occur with subjective outcomes, but may be avoided through blinding both researcher and study participants. However, if confounding bias is present for the association between the drug exposure and the outcome of interest, this may in select cases carry over to the assessment of interaction between the genetic variant and this drug exposure. 16 In the next sections we show that the degree to which different study designs are able to avoid or disentangle these considerations is paramount to the interpretation of results and conclusions that can be drawn, also in the field of pharmacogenetics.
| STUDY DESIGNS
Various studies are available and appropriate to answer different types of pharmacogenetic research questions, depending on the stage of drug development. Here we focus on those suitable to evaluate the effect of genetic variation on treatment efficacy and adverse drug reactions, questions which will typically be asked after a drug has already been approved for clinical use. In addition to post-hoc subgroup analyses within a randomised controlled trial (RCT), all traditional population-based epidemiological studies can be used in this phase. However, all study designs come with underlying assumptions and limitations, and may not be able to answer all relevant questions (Table 1) .
Our discussion here focuses mostly on sources of bias general to all epidemiology. However, a source of confounding specific to genetic epidemiology concerns population stratification. 17 If there exist subgroups of individuals within the study population which differ in terms of genotype frequency and disease risk, spurious associations may arise if this is not taken into account. Typically, this can occur when individuals from different ethnic backgrounds with limited admixture are included in the same analysis. 18 However, even apparently homogenous populations may contain genetically distinct subgroups. 19 As larger samples will likely be more heterogeneous, population stratification will be a larger problem here. 17 This should be of particular concern to researchers involved in the field of druggene interaction, where large studies are typically necessary to find promising signals.
| Outcome-based designs
The case-control design is perhaps the most common approach for pharmacogenetic investigations into clinical effects, often focusing on adverse drug reactions. Sampling is based on the outcome, with individuals who did (cases) develop the outcome of interest being compared to those who did not (controls), with regard to drug exposure prevalence and genotype frequencies. Case-control studies can be used to assess both main effects of the genetic variant and drug exposure on the outcome, but may also assess interaction on the additive and multiplicative scale 20 (Table 2 ).
There also exist case-control studies which solely include individuals with known drug exposure, in which the analysis is limited to comparing genotype frequency between cases and controls. For the FIGURE 2 Non-randomized study on treatment response. The observed treatment response to drug X depends not just on the underlying physiochemical response and natural course of the disease process, but also on secondary effects of being allocated drug X. Moreover, confounding by (contra)indication may occur if reasons to initiate or refrain from drug treatment also associate with the outcome of interest. Pharmacogenetic research aims to answer which, if any, inherited genetic factors explain variation in the outcome of interest in the presence of a certain (drug) treatment (ie, drug-gene interaction effects), distinguishing these effects from direct (ie, main genetic effects) on the outcome 23 This strategy may also be promising when rare variants are investigated, as their prevalence may be greater on the extreme ends of the outcome spectrum. 24 There are some notable challenges in performing case-control studies, the first and foremost being the selection of an appropriate control group. The control group should be representative of the source population in terms of exposure distribution and genetic ancestry (eg, European, Asian or African ancestry), and should ideally consist of individuals who would be classified as cases if they had developed the outcome of interest. In other words, controls should meet the eligibility requirements for cases except for their outcome status. 20 Preferably, a geographically defined population should be the source of sampling, so the entire at-risk population can be enumerated. For hospital-or clinic-based case-control studies it may be difficult to identify this source population, as it does not correspond to a specific geographical area. For example, trauma victims referred to the hospital could live nearby or have been flown in by helicopter.
In general, the catchment area for a hospital or clinic is likely to differ for different diseases, which will need to be considered when sampling controls. Similarly, as the cases of outcome-based studies on adverse drug reactions are often identified through databases it may be difficult to recruit an appropriate control group, especially because these events are often under-reported. 25, 26 Case-control studies nested within an existing cohort may fare better in this regard. A further risk is that cases with short survival times may be underrepresented if collection of (genetic) data occurs sometime after the event of interest.
An alternative outcome-based design is the case-only study, wherein the analysis is restricted to cases (Table 1 ). This simple approach, which can evaluate gene-treatment interaction on the multiplicative scale, assumes that genotype and drug treatment are not correlated in the population that gave rise to the cases. Under this assumption this design increases power for the test of interaction, thereby lowering the number of cases needed to be genotyped. 27 Not having or being able to find a suitable control group is another reason why this may be an attractive alternative to the conventional case-control study. 28 If nested in a RCT the distributions of gene and treatment can be assumed to be independent by virtue of randomisation, making the case-only odds ratio a valid measure of genetreatment interaction ( Table 2 ). The calculated odds ratio may however (slightly) differ between case-control and case-only studies, as case-control studies estimate different population parameters (odds-, rate-, or risk-ratio), depending on how the controls were sampled. 29 An example of the case-only approach in the field of statin pharmacogenetics is that by Schiffman et al, who performed a genome-wide association study on coronary heart disease risk reduction when being treated with pravastatin therapy. 30 In the discovery phase they solely included coronary heart disease cases from the Cholesterol and Recurrent Events (CARE) trial and the West of Scotland Coronary
Prevention Study (WOSCOPS) trial, finding that 79 common genetic variants were nominally (P < 10
) associated with differential event reduction by the therapy. To validate these results, these variants were then genotyped in an additional placebo-controlled pravastatin trial, and in all remaining patients from CARE and WOSCOPS (with or without event). 30 This study thereby exemplified how the case-only approach could be utilized as a cost-saving measure, by first screening the genome for promising signals, before including controls.
Nesting a case-only study within a cohort study can be problematic, as it is possible that genetic factors could influence the ability to tolerate therapy. Therefore, independence between genotype and treatment may not be a valid assumption. While this could also occur within a RCT, this experimental study design is more likely to have information on, and be able to include in the analysis, enrolled individuals who did not respond or had severe side effects. It has been argued that tests of gene-treatment association in controls may indicate whether genotype and treatment are truly independent in the source population, if the outcome is sufficiently rare. 31 If, however, the assumption of gene-treatment independence is violated and ignored, the case-only approach will provide a biased interaction effect and lead to increased false-negative results. 32 Another limitation of the case-only design is that main effects of either genetic or drug treatment on the outcome cannot be estimated, and inference is limited to examining interaction on the multiplicative scale. More generally, all outcome-based designs which cannot approximate risk ratios (rare disease assumption) or risk differences (due to knowing sampling fractions) are unable to examine interaction on the additive scale, which is often of greater public health relevance. 33 Due to their observational nature, outcome-based studies are additionally highly prone to confounding, selection bias (ie, that the association between (drug) exposure and disease differs for participants who were and
were not included in the study) and information bias (ie, systematic error in the approach adopted for measuring or collecting data from a study). 20 For the last category, especially recall bias can pose an issue, which will not apply to genotype but might to drug history.
| Cohort-based designs
Cohort-based designs include the cohort and treated-only designs (Table 1) . Typically, the rate of occurrence (or recurrence) is compared between individuals with different drug exposures levels.
Increasingly, population-based cohort studies are undertaken, in which an ideally random sample or even the entirety of a defined population is included in which multiple hypotheses can be evaluated.
Although these relatively expensive and time-consuming studies aim to answer the same questions of causality that outcome-based designs do, the extensive and repeated phenotyping and follow-up allows for more flexibility in investigating multiple outcomes and recent, prior and repeated drug exposure. 21 In addition, studying a cohort representative of a defined population allows for the calculation of population attributable risks. While this type of study typically includes more participants than outcome-based studies, it is unlikely that a single study would be able to overcome the power and sample size issues associated with genome-wide testing. Considerations of sample size are discussed in detail in a separate section below. As cohort-based designs do not typically allow for blinding of researchers and participants, it is very likely that observer effects will not be equal between the treatment groups. In addition, if genetic testing was not undertaken close to commencement of treatment, selection bias may occur when non-responders or those with severe side effects are absent from the population.
Of greater issue is that the assignment of drug therapy is likely to have been subject driven. This means that the prognoses of the treated and untreated subjects will generally not be alike. In addition to this previously discussed confounding by (contra)indication, the issue of regression-to-the-mean may be problematic here. This occurs because the group of subjects at the extremes of the response distribution at baseline not just consists of those who consistently have more extreme values compared to the population average, but also those who simply by chance had an extreme value at baseline. Subsequent measurements of those who fall in the second category will therefore tend to be closer to the population mean thereof. Observed phenotypic changes over time may thus (partially) represent this regression-to-the-mean, which can occur when participants and/or treatment are selected on phenotypic cut-offs at baseline. This statistical phenomenon has been demonstrated for a wide range of biological measures, including lipid levels. 34 Therefore, in non-randomised studies, it should be considered to combine multiple baseline measurements to reduce measurement error when selecting subjects, or to use suitable statistical methods.
35,36
The treated-only design essentially tries to limit the issue of confounding by contraindication whilst improving statistical efficiency. 37 As the name suggests, this design limits the analysis to those exposed to the drug, thereby leaving out the subjects who might have had a pertinent contraindication to treatment. This contrasts with cohorts which do include an untreated control group, in which confounding by (contra)indication is more commonly addressed through statistical adjustment, although applying stricter inclusion criteria at enrolment may also limit this issue. 14 A clear benefit of the treated-only approach is that fewer individuals are required for the analysis, which can be highly advantageous when genotyping study participants. As noted for the treated-only outcome-based design, the central assumption for inferring gene-treatment interaction effects here is that the genetic variant is unlikely to explain change in outcome in absence of the drug exposure. 21 A clear drawback are that the main effects of genetic variants on the outcome are inseparable from drug-treatment interaction effects. Observed loci may thus be associated with the 
Treated-only case-control setting (subset of frequency data)
Drug (E) Genotype (G) Cases Controls Treated-only case-control OR = f × g/e × h − − n/a n/a If the genetic variant G is not associated with the outcome among untreated individuals (OR G = 1), the treatment-only case-control OR will estimate the assessment of interaction on the multiplicative scale from the case-control setting − + n/a n/a
Case-only setting (subset of frequency data)
Drug (E) Genotype (G) Cases Controls Case-only OR = a × g/c × e − − a n/a If the drug treatment E and genetic variant G are not associated among controls (ie, source population), the caseonly OR will estimate the assessment of interaction on the multiplicative scale from the case-control setting
Abbreviation: OR, odds ratio. While the above table denotes genotype as the presence of absence of a certain susceptibility genotype, it will equally hold for more complex situations, including combinations of alleles at multiple loci. a To assess for interaction on the multiplicative scale: OR GE /(OR G × OR E ).
natural course of the disease. 37 In these cases, leveraging publically available data from genome-wide association studies (GWAS) may help to substantiate the claim of absence of a main effect of a genetic variant on the outcome of interest. This approach will, however, require these GWAS to have taken into account possible effects of drug treatment and to have a similar outcome definition.
Of special note, an increasing number of researchers are utilizing (singular or repeated) cross-sectional data from cohort studies to perform genome-wide gene-treatment interaction analyses for quantitative traits. 38 These efforts have largely been motivated by the issue that the design of many cohorts is not ideal for measuring longitudinal drug-induced changes. Specifically, assessment may be problematic when drug exposures are rare, when large intervals of time separate repeat drug exposure assessment, and when outcome phenotypes are not collected at each study visit. Therefore, the use of repeated exposure cross-sections allows for more cohorts to contribute, noting that increases in power from including more participants has been shown to be larger than the modest increase in power from making use of repeat cross-sectional measures in the same participants. 39 To date, this approach has particularly been applied to questions of gene-treatment interaction for different drug classes on electrocardiography markers. 39, 40 Similar research efforts are currently underway for the field of statin pharmacogenetics.
As study information on exposure and outcome is typically determined at the same time, or at least analysed without regard for differences in time, the temporal relationship between exposure and outcome remains unclear in these cross-sectional analyses. In fact, making a distinction between exposure and outcome will generally not be possible, unless a well-established drug response phenotype is available. 20 Furthermore, aside from the issues discussed previously concerning the use of a single on-treatment measurement, care must be taken to differentiate effects from those on off-treatment values.
Therefore, formal comparison with an untreated group is to be advised.
Alternative explanations for detected associations between genotype and outcome may be differences in number and duration of previous treatment(s) and differences in severity of disease. Using data from established cohorts may greatly facilitate the execution of these investigations. Nonetheless, due to their inherent limitations, cross-sectional studies are most suitable as hypothesis-generating tools for slowly developing diseases without sharp onset times, rather than for making solid pharmacogenetic inferences of gene-treatment interaction.
| Randomized controlled trial
While similar in design to a cohort with a control group, the key difference for the RCT is that drug treatment is randomly allocated. As this ensures that the predictors of the outcome are equally distributed between the treated and untreated group, we can assume that:
"the treated, had they remained untreated, would have experienced the same average outcome as the untreated did, and vice versa". 41 In addition, this strategy enables blinding of researcher and participant, which aims to prevent subsequent differential co-interventions or biased assessment of outcomes. 42 As previously noted, if the trial is of adequate size the distributions of genotype and exposure will be independent. Due to these study characteristics, it is possible to either avoid or account for regression-to-the-mean, confounding by (contra)indication and selection bias. Consequently, it is possible to make more firm conclusions regarding the underlying treatment effects than is possible in non-randomised studies (Figure 2) . While reducing the likelihood of selection bias is a major appeal of RCTs, it should be noted that genotyping in blood samples taken after study completion may still introduce this problem.
Subgroup analyses in trials have also been criticised, 43 were recently used to show that genetic predisposition for increased LDL-C levels may decrease efficacy of statin therapy if effects on offtreatment lipid levels are taken into account. 46 Mendelian randomisation might alternatively be used to predict unintended drug effects.
For example, Swerdlow et al used SNPs in the HMGCR (ie, the enzyme targeted by statins) gene to show that the increase in newonset type 2 diabetes risk is "at least partially" explained by HMGCR inhibition. 47 In theory, Mendelian randomisation investigations could reveal these effects prior to drugs licensing, potentially preventing exposure of large groups of patients to unnecessary risks. 48 Lastly, stratifying Mendelian randomisation analyses could provide evidence which subpopulations are likely to derive greater benefit from a drug, which could guide future RCTs. 49 
| CONSIDERATIONS OF SAMPLE SIZE
A major issue in pharmacogenetic research has been the poor reproducibility of promising signals, likely in part due to underestimation of the sample sizes necessary to examine gene-treatment interaction. It has previously been demonstrated that study sizes for investigations into interaction on the multiplicative scale should be over 4 times as large as those necessary to detect main effects of the same magnitude. 50 Given the relatively small effect sizes involved, it should therefore not come as a surprise that necessary sample sizes can run into the tens of thousands when genome-wide strategies are considered, where one must not just account for multiple testing but also consider the necessity of replicating ones results. 51 Programs for sample size and power calculations for gene-treatment interaction have also been used to estimate sample size requirements for investigations into clinical effects of statin therapy. 5 In addition to study design, researchers must consider the expected sizes of both the genetic effect and the drug response, the size of their interaction effects, allele frequencies, mode of inheritance, and the prevalence of the drug treatment and outcome. Moreover, studies are likely to genotype variants in linkage disequilibrium with the true causal variant, which will also influence sample size requirements. 52 In recent years, data from mega-biobanks have become increasingly available, which will provide unprecedented possibilities for pharmacogenetic enquiries. It should however be noted that participation rates have been relatively low, which will pose unique challenges when interpreting results. For example, only 5.2% of the 9.2 million individuals invited to enter the population-based UK Biobank actually participated in the baseline assessment. 53 Similarly, in mid-2015 the Million Veterans Program estimated their response rate at 13.2% of the first 3 million invited individuals. 54 In addition, it is highly questionable whether signals which can only be detected under these increased sample sizes will actually translate into clinically meaningful results.
Further considerations must be made when multiple study designs are incorporated in the same analysis via a meta-analytic approach. In the next section we will examine some of these considerations, taking the largest pharmacogenetic meta-analysis of genome-wide association studies of statin-induced LDL-C changes as an example. ).
Notably, the consortium solely included statin users, which made it possible to compare associations found in trials with those of observational studies. In addition, this approach made it possible to gather large enough numbers, given the necessity to account for multiple testing. To mimic the trial setting as close as possible, only incident statin users with a pre-and post-measurement were included from observational studies.
As discussed previously, the central assumption for inferring gene-treatment interaction effects via this treated-only approach is that genotype should be unlikely to significantly correlate with the response in absence of drug exposure. Given that the underlying disease course (ie, LDL-C levels) can be assumed to be quite stable in absence of lipid-lowering treatment, this assumption may very well be valid. In addition, placebo-and observer-effects will likely be near absent for statin-induced LDL-reduction, which will exist for more subjective complaints such as those seen within the field of psychiatric pharmacogenetics. 56 The suitability of this approach was reinforced by the large homogeneity of estimates when RCTs and observational studies were separately considered.
A major point of discussion, however, surrounded the question how to account for the possible effect of genetic variants on offtreatment values, which cannot simply be accounted for by taking the (fractional) difference between on-and off-treatment levels as the outcome. In the end, the researchers solely included participants with on-and off-treatment LDL-C levels. Each study independently performed a GWAS on the difference between the natural logtransformed LDL-C levels on-and off-treatment which can be interpreted as the fraction of differential LDL-C lowering in carriers vs non-carriers of a genetic variant. These analyses were then adjusted for natural log-transformed off-treatment values to try to distinguish drug-treatment interaction effects from genetic effects on offtreatment LDL-C levels, a strategy for which there exists extensive debate, particularly for non-randomised studies. 57, 58 By performing additional analyses, the researchers were, however, able to validate this approach. These included calculating formal gene-treatment interaction terms within a trial not involved in the first-stage metaanalysis for the genetic variants found to be genome-wide significant, but also by adjusting for the measurement error and intra-individual variation in off-treatment values in the only study which had multiple baseline measurements available. 59 The main limitation of the analysis is the large degree of clinical heterogeneity. This is evidenced not only by differences in eligibility criteria of the original studies, leading to the inclusion of different patient groups, but also by differences in statin types (n = 8) and dosages. While adjustment for statin dose was achieved by dividing the dose by the statin-specific dose equivalent based on daily dosages required to achieve mean 30% LDL-C reduction, changes in dose during follow-up could not be taken into account. Nonetheless, the project remains a clear example that if certain assumptions can be realistically met, inherent limitations to pharmacogenetic inference may be overcome.
| CONCLUSION
Pharmacogenetic research is an expanding field, whose relevance is slowly becoming visible. While post-hoc subgroup comparisons in RCTs are still considered the gold standard in pharmacogenetic research of treatment efficacy, there exist many research questions for which RCTs cannot provide the solution. As all study designs and response phenotypes have their merits and problems, authors should be vigilant to avoid making conclusions which their methodology cannot back up. In particular, the assumptions needed to make inferences on gene-treatment interaction must be carefully considered, especially when case-or treated-only strategies are employed. These challenges to inference remain ever relevant as new avenues of pharmacogenetic investigations emerge, including those using epigenetics or mRNA, as these studies will typically be performed in similar research settings.
